Physician
West Chester Hospital LLC
West Chester Hospital LLC was paid $19.60M by Medicaid between Jan 2018 and Dec 2024, across 313 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 16% of everything it billed.
33Billing provider infoWEST CHESTER HOSPITAL LLC
WEST CHESTER, OH 45069
WEST CHESTER, OH 45069
33aNPI1851549273assigned 08/28/2008
33bProvider typeInternal Medicine Physician
28Total paid$19.60M
24GClaims501,649
24DCodes billed313
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in Ohio
Rank by total paid#3 of 663
Median peer was paid$17K
This provider vs. median1,125×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,344 | $1.88M | |
| 2019 | 39,536 | $1.62M | |
| 2020 | 19,710 | $972K | |
| 2021 | 29,370 | $1.40M | |
| 2022 | 33,430 | $1.74M | |
| 2023 | 199,149 | $7.71M | |
| 2024incomplete | 134,110 | $4.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 16% | 33,334 | 28,687 | $3.15M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 10% | 32,887 | 29,580 | $2.05M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.7% | 16,771 | 14,646 | $1.89M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.8% | 14,883 | 13,449 | $1.53M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 5.7% | 1,276 | 1,157 | $1.11M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.8% | 2,728 | 2,014 | $741K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.7% | 6,022 | 4,961 | $727K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 2,966 | 2,298 | $657K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.7% | 1,474 | 1,332 | $521K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 2,725 | 2,030 | $354K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.7% | 3,293 | 2,729 | $341K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.7% | 1,300 | 936 | $325K |
301 more codes
| 64615 | 1.5% | 1,229 | $301K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 1,906 | $295K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.4% | 1,243 | $282K |
| 20610 | 1.4% | 2,119 | $271K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.2% | 1,689 | $236K |
| G0378 | Hospital observation service, per hour | 1.1% | 2,839 | $209K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,570 | $193K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 617 | $143K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 410 | $137K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 615 | $134K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 339 | $133K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 579 | $130K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,315 | $126K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 775 | $126K |
| 43235 | <1% | 320 | $109K | |
| 62323 | <1% | 290 | $107K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 169 | $104K |
| 59025 | Fetal non-stress test | <1% | 680 | $104K |
| 70496 | <1% | 457 | $100K | |
| 31231 | <1% | 603 | $97K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 14,803 | $94K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 648 | $93K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 766 | $92K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,012 | $89K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 163 | $85K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,265 | $78K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 487 | $75K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,420 | $74K |
| 31579 | <1% | 327 | $71K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 420 | $65K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 526 | $64K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 592 | $62K |
| 93308 | <1% | 259 | $60K | |
| 71250 | <1% | 710 | $58K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 722 | $57K |
| 82805 | <1% | 2,264 | $54K | |
| 76642 | <1% | 421 | $49K | |
| 72141 | <1% | 401 | $48K | |
| 80053 | Comprehensive metabolic panel | <1% | 10,204 | $48K |
| 76801 | <1% | 402 | $43K | |
| 95811 | <1% | 66 | $41K | |
| 76770 | <1% | 348 | $40K | |
| 31575 | <1% | 278 | $37K | |
| 94060 | <1% | 390 | $37K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 201 | $36K |
| 92557 | <1% | 834 | $36K | |
| 86850 | <1% | 2,208 | $35K | |
| 93017 | <1% | 464 | $34K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 273 | $34K |
| 72100 | <1% | 2,386 | $33K | |
| 76000 | <1% | 540 | $32K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 845 | $31K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 318 | $31K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,900 | $31K |
| 76830 | Ultrasound, transvaginal | <1% | 737 | $30K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 861 | $29K |
| 74018 | <1% | 924 | $28K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 62 | $26K |
| 93971 | <1% | 349 | $25K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 40 | $25K |
| 73630 | <1% | 1,836 | $25K | |
| 86900 | <1% | 2,587 | $25K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,609 | $25K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 108 | $23K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 223 | $21K |
| 94729 | <1% | 498 | $21K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,103 | $21K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 113 | $19K |
| 36415 | Collection of venous blood by venipuncture | <1% | 38,605 | $19K |
| 73030 | <1% | 1,332 | $18K | |
| 72040 | <1% | 848 | $18K | |
| 84484 | <1% | 6,371 | $17K | |
| 94726 | <1% | 365 | $17K | |
| 76536 | <1% | 195 | $16K | |
| 73130 | <1% | 974 | $16K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 154 | $16K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 403 | $15K |
| 77080 | <1% | 255 | $15K | |
| 70491 | <1% | 79 | $15K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 180 | $15K |
| 70498 | <1% | 380 | $14K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 747 | $13K |
| 73562 | <1% | 925 | $13K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,002 | $12K |
| 85027 | <1% | 2,789 | $12K | |
| 73610 | <1% | 1,125 | $12K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,019 | $11K |
| 72156 | <1% | 115 | $11K | |
| 73560 | <1% | 944 | $10K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 836 | $10K |
| 83880 | <1% | 3,342 | $8K | |
| 73221 | <1% | 39 | $8K | |
| 76937 | <1% | 282 | $8K | |
| 73502 | <1% | 754 | $8K | |
| 80320 | <1% | 745 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,633 | $7K |
| 82248 | <1% | 8,693 | $7K | |
| 62329 | <1% | 17 | $7K | |
| 77336 | <1% | 57 | $7K | |
| 80069 | <1% | 563 | $7K | |
| 73110 | <1% | 612 | $6K | |
| 97162 | <1% | 238 | $6K | |
| 64483 | <1% | 15 | $6K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 40 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,142 | $6K |
| 88307 | <1% | 57 | $6K | |
| 74183 | <1% | 30 | $6K | |
| 86901 | <1% | 2,579 | $6K | |
| 81001 | <1% | 8,917 | $6K | |
| 97165 | <1% | 185 | $6K | |
| 73564 | <1% | 739 | $6K | |
| 93975 | <1% | 63 | $6K | |
| 92550 | <1% | 63 | $5K | |
| 95976 | <1% | 56 | $5K | |
| C8908 | Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral | <1% | 16 | $5K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 216 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,339 | $5K |
| 93296 | <1% | 257 | $5K | |
| 70486 | <1% | 78 | $5K | |
| 83735 | <1% | 3,993 | $5K | |
| 95816 | <1% | 37 | $5K | |
| 51784 | <1% | 30 | $5K | |
| 77065 | Tomosynthesis, mammo | <1% | 269 | $5K |
| 51728 | <1% | 30 | $4K | |
| 85610 | <1% | 3,081 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 37 | $4K |
| 72110 | <1% | 252 | $4K | |
| 74240 | <1% | 30 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,987 | $4K |
| J3490 | Unclassified drugs | <1% | 263 | $4K |
| 81003 | <1% | 2,565 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 11,050 | $4K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,347 | $4K |
| 72146 | <1% | 43 | $4K | |
| 97161 | <1% | 107 | $3K | |
| 90715 | <1% | 260 | $3K | |
| 49083 | <1% | 24 | $3K | |
| 20550 | <1% | 23 | $3K | |
| 72131 | <1% | 78 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,625 | $3K |
| 92567 | <1% | 570 | $3K | |
| 73590 | <1% | 346 | $3K | |
| 20553 | <1% | 29 | $3K | |
| 72082 | <1% | 198 | $3K | |
| 83690 | <1% | 6,290 | $3K | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 817 | $3K |
| 77061 | <1% | 105 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,053 | $2K |
| 77062 | <1% | 79 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 912 | $2K |
| 81025 | <1% | 5,356 | $2K | |
| 88738 | <1% | 377 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,680 | $2K |
| 78264 | <1% | 12 | $2K | |
| 93970 | <1% | 13 | $2K | |
| 72050 | <1% | 124 | $2K | |
| 84100 | <1% | 1,396 | $2K | |
| 96367 | <1% | 100 | $2K | |
| 82565 | <1% | 461 | $2K | |
| 72070 | <1% | 123 | $2K | |
| 86140 | <1% | 338 | $2K | |
| 84439 | <1% | 689 | $2K | |
| 72170 | <1% | 391 | $2K | |
| 84703 | <1% | 2,235 | $2K | |
| 83605 | <1% | 2,008 | $2K | |
| 76820 | <1% | 60 | $2K | |
| 85730 | <1% | 1,198 | $2K | |
| 84702 | <1% | 543 | $2K | |
| 73700 | <1% | 19 | $2K | |
| 93299 | <1% | 84 | $2K | |
| 74455 | <1% | 12 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,500 | $1K |
| 72157 | <1% | 39 | $1K | |
| 96376 | <1% | 1,096 | $1K | |
| 01999 | <1% | 1,015 | $1K | |
| 87210 | <1% | 675 | $1K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 186 | $1K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 472 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 196 | $1K |
| 77066 | Tomosynthesis, mammo | <1% | 101 | $1K |
| 73620 | <1% | 105 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,768 | $1K |
| 87077 | <1% | 597 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,289 | $969.37 |
| 97166 | <1% | 50 | $948.98 | |
| 51798 | <1% | 107 | $915.82 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 4,528 | $859.14 |
| 73552 | <1% | 124 | $849.14 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,831 | $843.14 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,224 | $820.04 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 32 | $818.59 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 18 | $771.02 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,801 | $738.19 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,067 | $697.59 |
| 93922 | <1% | 16 | $693.31 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 777 | $685.36 |
| Q3014 | Telehealth originating site facility fee | <1% | 286 | $653.18 |
| 73600 | <1% | 14 | $637.55 | |
| C1769 | Guide wire | <1% | 467 | $622.46 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,631 | $617.08 |
| 43450 | <1% | 149 | $608.49 | |
| 87186 | <1% | 538 | $545.47 | |
| 85379 | <1% | 636 | $535.26 | |
| 88342 | <1% | 1,494 | $484.81 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 133 | $469.87 |
| 85652 | <1% | 342 | $461.50 | |
| 84520 | <1% | 269 | $443.27 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,153 | $439.62 |
| 97116 | <1% | 28 | $435.96 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,872 | $429.93 |
| 82330 | <1% | 478 | $426.48 | |
| 73070 | <1% | 39 | $426.15 | |
| 00731 | <1% | 570 | $411.08 | |
| 87040 | <1% | 345 | $392.07 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 54 | $383.81 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 955 | $332.46 |
| 00811 | <1% | 266 | $331.68 | |
| 84132 | <1% | 544 | $312.58 | |
| 51705 | <1% | 21 | $290.62 | |
| 85014 | <1% | 612 | $285.03 | |
| 51702 | <1% | 46 | $259.90 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,902 | $257.60 |
| 88341 | <1% | 44 | $256.89 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 618 | $253.92 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,576 | $248.17 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 421 | $237.81 |
| 80329 | <1% | 319 | $231.99 | |
| 85018 | <1% | 652 | $218.51 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 219 | $213.12 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 728 | $198.57 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 61 | $196.14 |
| 82550 | <1% | 165 | $193.92 | |
| 92504 | <1% | 878 | $187.31 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 250 | $181.52 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 139 | $176.74 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 54 | $171.86 |
| 86780 | <1% | 30 | $164.53 | |
| 36591 | <1% | 18 | $146.29 | |
| 82607 | <1% | 44 | $145.97 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 891 | $143.53 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 846 | $137.77 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 34 | $133.66 |
| 82947 | <1% | 448 | $112.30 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 702 | $111.14 |
| 87070 | <1% | 341 | $99.38 | |
| 84295 | <1% | 433 | $89.60 | |
| 88304 | <1% | 62 | $77.53 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 20 | $77.27 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,373 | $70.07 |
| 87205 | <1% | 265 | $69.47 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 28 | $67.51 |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 44 | $63.03 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 286 | $57.75 |
| 82746 | <1% | 31 | $56.71 | |
| Q9956 | Injection, octafluoropropane microspheres, per ml | <1% | 176 | $55.36 |
| 82040 | <1% | 15 | $55.36 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 392 | $55.02 |
| 80061 | Lipid panel | <1% | 21 | $53.99 |
| 82570 | <1% | 34 | $52.11 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 617 | $45.94 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 132 | $43.17 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 141 | $35.30 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 143 | $34.92 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 992 | $31.18 |
| 95886 | <1% | 86 | $29.62 | |
| J1815 | Injection, insulin, per 5 units | <1% | 88 | $29.12 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 116 | $21.97 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 46 | $20.32 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 699 | $19.95 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 322 | $19.69 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 66 | $15.28 |
| 73060 | <1% | 17 | $13.07 | |
| 69210 | <1% | 13 | $11.69 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 277 | $11.27 |
| 89051 | <1% | 116 | $10.34 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 55 | $9.06 |
| 36416 | <1% | 367 | $6.25 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 207 | $4.23 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,457 | $4.17 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 193 | $2.31 |
| 84157 | <1% | 52 | $0.79 | |
| 82945 | <1% | 51 | $0.79 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 87 | $0.10 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 12 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 77 | $0.00 |
| 77077 | 0% | 44 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 18 | $0.00 |
| 00300 | 0% | 24 | $0.00 | |
| 00840 | 0% | 52 | $0.00 | |
| 01630 | 0% | 18 | $0.00 | |
| 73140 | 0% | 17 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 14 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 15 | $0.00 |
| 01400 | 0% | 90 | $0.00 | |
| 94760 | 0% | 76 | $0.00 | |
| 73090 | 0% | 13 | $0.00 | |
| 87015 | 0% | 92 | $0.00 | |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 51 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 52 | $0.00 |
| 00813 | 0% | 16 | $0.00 | |
| 82435 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHINDS, HUGH (EXECUTIVE VP & CFO)
Parent organizationUC HEALTH
| Provider | Location | Paid |
|---|---|---|
| University of Cincinnati Medical Center, LLC | Cincinnati, OH | $176.53M |
| University of Cincinnati Physicians Company, LLC | Cincinnati, OH | $65.09M |
| University Surgical-Dental Associates, LLC | Cincinnati, OH | $8.15M |
| Daniel Drake Center for Post-Acute Care, LLC | Cincinnati, OH | $5.55M |
| University of Cincinnati Physicians Company LLC | Cincinnati, OH | $5.47M |
| University of Cincinnati Medical Center, LLC | Cincinnati, OH | $614K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.